Orbit Discovery has announced that Dr Mario Polywka has joined their board as a non-executive director.
Mario Polywka brings exceptional operational, commercial and strategic development experience to the company, having retired as chief operating officer of Evotec recently after 12 years in the role, he now sits on their supervisory board. He is also a member of the board of Forge Therapeutics Inc. and Exscientia Ltd. Previously, he held COO, CEO, chairman and non-executive director positions within Evotec and Oxford Asymmetry International as well as a number of Oxford and Southampton University spin-out companies.
Alex Batchelor, CEO of Orbit said that Mario’s appointment “further strengthens our board as we take Orbit into our next growth phase. His commercial and operational experience with Evotec supports both our partnered discovery programmes and our internal discovery efforts. As we continue to build our platform and create a powerful tool for both peptide therapeutics discovery and T-cell target identification we’re confident that Mario’s pragmatic and supportive approach will benefit not just our board, but our broader team and our partners.”
